Transmembrane protease serine 2

TMPRSS2 (Transmembrane protease serine 2) is a membrane protein belonging to the type II transmembrane serine protease (TTSP) family. It is functionally classified as a trypsin-like protease (TLP). Serine proteases are known to be involved in many physiological and pathological processes, but the exact function remains unclear. It is involved in two main pathological processes, prostate cancer and viral entry. TMPRSS2 is expressed in several tissues regulated by androgens and undergoes autocatalytic cleavage for its activation.

spinqualitylabelsall models Crystal structure of human TMPRSS2 in complex with Nafamostat Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Protease activity TMPRSS2, as a serine protease, cleaves peptide bonds present after positively charged residues (lysine or arginine). The main player in the catalytic mechanism is the catalytic triad formed by His296, Asp345, and Ser441. These three aminoacids are located in the active site of the enzyme. The substrate specificity is achieved with the presence of a negatively charged Asp residue at the bottom of a cavity usually indicated as “S1 specificity pocket”. Structure Gene The TMPRSS2 gene resides on chromosome 21 at the band 21q22.3, extends aproximately 43.59 kb and is split into 14 exons. This gene is conserved in a wide variety of animals, such as chimpanzee, Rhesus monkey, dog, cow, mouse, rat, chicken, zebrafish, Caenorhabditis elegans and frog. It presents two alternative splicing variants resulting in a 3.25 kb and 3.21 kb transcripts, respectively. Protein TMPRSS2 is a 492 amino acid single-pass type II membrane protein. This protein is defined by the presence of an N-terminal cytoplasmic domain, a transmembrane helical domain (aa 84-106), and three extracellular domains: TMPRSS2 protein domains Low-density lipoprotein (LDL)-receptor class A domain: which forms a binding site for calcium. Expands from amino acid 113 to 148. Scavenger receptor cysteine-rich domain (SRCR) of group A from amino acid 149 to 242. Peptidase S1 domain, also known as serine protease domain (SPD) from amino acid 255 to 492. Schematic representation of TMPRSS2 structure: TM is the transmembrane domain, LDL receptor class A domain and SRCR (scavenger receptor cysteine rich domain) form the stem region. The serine protease domain is composed by the catalytic amino acid triad histidine, aspartic acid and serine, essential for proteolytic activity. Expression TMPRSS2 is predominantly expressed in prostate, with relatively lower level of expression in type II pneumocytes in lungs, colon, small intestine, stomach, salivary glands, liver, kidneys and pancreas. Autocatalytic cleavage As TMPRSS2 is synthesized as a single-chain proenzyme, or zymogen, it requires cleavage at a conserved Arg255-Ile256 peptide bond within its SRQSR255↓IVGGE activation motif (cleavage site denoted with an arrow) to achieve full maturation of its enzymatic activity. This autocatalytic cleavage activates the 492-residue long TMPRSS2 zymogen. This modification enables the binding of Ile256 into a putative allosteric pocket (A-pocket), which induces a conformational rearrangement of the catalytic site. After the cleavage, TMPRSS2 remains bound to the transmembrane N-terminal domains by a conserved disulfide bond, although a small fraction of the protein can be detected into the extracellular environment, the protease domain of this protein is thought to be cleaved and secreted into cell media after autocleavage. Regulation The human TMPRSS2 gene promoter has a 15-bp androgen response element. The upregulation of TMPRSS2 mRNA by androgens appears to be mediated by the androgen receptor. General function In terms of normal function, TMPRSS2 has been associated with physiological and pathological processes such as digestion, tissue remodelling, blood coagulation, fertility, inflammatory responses, tumour cell invasion, apoptosis and pain. In the lung, it has been suggested that it regulates epithelial sodium currents through proteolytic cleavage of the epithelial sodium channel. However, knock out mice showed no obvious phenotypic abnormality such as death, infertility or visible sickness, and the exact physiological function of TMPRSS2 in vivo remains unknown. It is speculated that TMPRSS2 may contribute to a specialised but non vital function. Clinical relevance Prostate cancer Prostate cancer (PC) is the most common form of cancer found in American men and the second leading cause of cancer death. This means that approximately 28.5% of cancers and 3.5% of cancer related deaths in men are due to PC. The most prevalent chromosomal aberration causing this pathology is the fusion of the the promoter of transmembrane protease serine 2 (TMPRSS2) gene and the coding sequence of the erythroblastosis virus E26 (Ets) gene family members. Ets family members are oncogenic transcription factors. Therefore, the fusion of these genes leads to the production of Ets transcription factors under the control of the androgen sensitive promoter elements of TMPRSS2. Specifically, the TMPRSS2-ERG fusion has been identified in approximately 50% of PC cases, responsible for driving carcinogenesis. This mutation occurs through chromosomal translocation or intergenic deletion, with both genes on the same arm of chromosome 21, and results in overexpression of chimeric mRNA of ERG in response to androgens. There is impairment of apoptosis in TMPRSS2-ERG positive cancer cells, possibly due to disruption of the intracellular death domain or decoy receptors. The high prevalence of these gene fusions, in particular TMPRSS2-ERG, makes them attractive as potential diagnostic and prognostic indicators, as well as making them a potential target for tailored therapies. Viral entry TMPRSS2 facilitates the entry of viruses into host cells by proteolytically cleaving and activating viral envelope glycoproteins (viral spike protein). As human TMPRSS2 is expressed in cells of the respiratory tracts, in addition to the epithelia of the gastrointestinal and urogenital systems, it mediates the entry of several viruses related to respiratory diseases into the host cells, including Influenza virus and the human coronaviruses HCoV-229E, MERS-CoV, SARS-CoV and SARS-CoV-2 (COVID-19 virus) . Viral entry mediated by TMPRSS2. SARS-CoV-2 SARS-CoV-2 entry is achieved by a receptor-mediated endocytosis pathway in which the spike (S) glycoprotein, located on the outer envelope of the virus, interacts with the host angiotensin-converting enzyme 2 (ACE2), a receptor located in the surface of host cells, which allows the virus to infect cells. Prior to this interaction, S protein is needed to be cleaved by different protease enzymes (furins, cathepsins, serine proteases) . SARS-CoV-2 S protein presents two functional domains S1, the receptor binding domain, and S2, that contains functional elements involved in membrane fusion. There are multiple sites in which this protein can be cleaved; one of these is at the S1/S2 boundary and another within S2. The S1/S2 cleavage site contains multiple arginine residues, which allows the action of serine proteases . Coronaviridae family tend to prefer "TMPRSS2" for the cleavage of S protein over other proteases, such as the endosomal cathepsins. As this protease is expressed in SARS-CoV-2 target cells throughout the human respiratory tract, it is also required for the spread of this virus. However, it has been demonstrated to be dispensable for the development or homeostasis of mice models, so it can be considered a potential target to fight the infection of these viruses. Schematic representation of the cleavage sites in TMPRSS2 protein structure. Pharmacological therapeutic approaches Inhibitors of TMPRSS2 Nafamostat mesylate Nafamostat mesylate (FUT-175; CAS number: 81525-10-2) is an artificial serine protease inhibitor clinically approved in Japan for the treatment of acute pancreatitis, intravascular coagulation dissemination, and extracorporeal circulation antioxidation. Although nafamostat potently neutralizes TMPRSS2 activity, it is non-selective and disables trypsin-like serine proteases involved in coagulation such as plasmin, FXa, and FXIIa, as well as other TTSPs through its generic arginine-like engagement with the S1 subsite. Also, it requires continuous intravenous infusion to approach therapeutic concentrations for COVID-19 owing to its short biological half-life of 8 minutes. Close-up view of the SP catalytic triad residues and the post-activation Asp440:Ile256 salt bridge showing complete maturation of the protease. Nafamostat treatment results in phenylguanidino acylation of Ser441. Polar contacts are shown as yellow dashed lines. Camostat mesylate Camostat is a serine protease inhibitor used in the treatment of cancer, pancreatitis and liver fibrosis. A recent study demonstrated that the inhibition of TMPRSS2 with camostat led to a 10-fold reduction in SARS-CoV titers in Calu-3 cells. Nafamostat vs. Camostat mesylate Nafamostat and Camostat are competitive inhibitors of the binding active site. They are both reactive esters that form the same slowly-reversible phenylguanidino covalent complex with the catalytic serine (Ser441) residue of trypsin-like serine proteases. However, Nafamostat demonstrated enhanced potency over camostat with IC50 values of (1.7±0.2) and (17±4) nM, respectively. Nafamostat has demonstrated being able to block MERS-CoV infection in vitro via inhabiting the activity of TMPRSS2, and reduce viral entry by 100-fold at a concentration of as low as 1 nM, which is more effective than camostat. Cell viability of Calu3 cell line treated with Gabexate (grey), Nafamostat (red) and Camostat (pink). Entry efficiency of SARS-2-S in Calu3 cell line treated with Gabexate (grey), Nafamostat (red) and Camostat (pink). Bromhexine Bromhexine is a mucolytic agent that acts as a TMPRSS2 inhibitor. Given that BHH is an FDA approved drug with no significant adverse effects, it could be used for treatment of influenza virus and coronavirus infections. However, recent studies have shown this drug has no effectiveness in blocking SARS-CoV-2 pseudovirus entry and further research is needed regarding the design of novel and more selective TMPRSS2 inhibitors. It has also been proposed for attenuation of prostate cancer in mice. TMPRSS2 peptidase activity blocked by clinical protease inhibitors, with no inhibition seen for bromhexine. Transcriptional inhibition Transcriptional inhibition of TMPRSS2 has been proposed as a new therapeutic option. As TMPRSS2 expression seems to be modulated by estrogens and androgens, data suggest that the activation of estrogen pathways or inhibition of androgen pathways may be a new target for therapeutic clinical intervention for symptom amelioration in COVID-19 patients. In fact, according to this same study estrogen-related compounds and androgen receptor antagonists appear to be the most securely identified down-regulators of TMPRSS2 expression amongst FDA approved drugs and other widely tested compounds. TMPRSS2 modulators: (A) chemical structure of TMPRSS2 inhibitors and (B) some transcriptional inhibitors.

Proteopedia Page Contributors and Editors (what is this?)

Ines Muniesa-Martinez, Paula R. Mallavibarrena, Laura Aleixos Juan, Michal Harel, Jaime Prilusky